Previous 10 | Next 10 |
ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ende...
ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the addition...
BioCorRx ([[BICX]]) posted a wider first-quarter net loss and said that it had "substantial doubt" about being able to continue as a going concern.The company believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve mo...
BioCorRx (BICX): Q1 GAAP EPS of -$0.26.Revenue of $0.01M (-75.0% Y/Y)Shares +3.96% PM.10QPress Release For further details see: BioCorRx reports Q1 results
ANAHEIM, CA, May 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business...
BioCorRx (BICX) announces that the U.S. FDA has given the company clearance to proceed to human trials for BICX104, an implantable naltrexone pellet for the treatment of Opioid Use Disorder ((OUD)).BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed ...
ANAHEIM, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the ...
BioCorRx (BICX) announces that the company has filed an Investigational New Drug ((IND)) application with the U.S. FDA for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder ((OUD)).BICX104 is a biodegradable, long-acting subcu...
ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Co...
ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and repor...
News, Short Squeeze, Breakout and More Instantly...
ANAHEIM, CA - ( NewMediaWire ) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2024, and...
ANAHEIM, CA - ( NewMediaWire ) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmace...
ANAHEIM, CA - ( NewMediaWire ) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on...